The Massachusetts-based company will use the funds to advance its Spectris neurotechnology platform that uses visual and auditory stimulation to treat Alzheimer’s disease.

Series C proceeds position Spectris for pivotal top-line data, regulatory submission, and launch planning ahead of a targeted ...

Firstly, the authors provided a detailed explanation of the experimental methods and procedures. This study recruited 30 healthy subjects (15 males and 15 females), aged between 20 to 50 years, with ...